Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Glucagon-like peptide 1 (GLP1) analogues

The future of diabetes management has begun

    • Cardiology
    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Partner Content
    • RX
  • 2 minute read

Diabetes does not hurt – one would almost like to add “unfortunately”. This is because the number of unreported cases of affected patients is still high. Possible late effects of the disease, especially if it is not treated or treated late, can be serious. In the process, the therapy has been steadily improved in recent years. Glucagon-like peptide 1 (GLP1) analogs have also provided a new treatment option that works quickly and effectively.

Diabetes mellitus is a serious disease that is a high risk factor for comorbid diseases, especially cardiovascular disease. It is estimated that around 500,000 people in Switzerland are affected. However, about half of those affected are still unaware of their disease. On average, it takes seven years for the diagnosis to be made. Valuable time that could already be used effectively for treatment. The sooner blood glucose levels can be adjusted through sufficient exercise, a balanced diet and adequate drug therapy, the sooner acute symptoms and late effects can be avoided. Current guidelines recommend lifestyle modification and the use of metformin as first-line treatment for type 2 diabetes mellitus (Fig. 1) . The HbA1c value is still considered the glycemic standard for long-term therapy management. However, there has now been a shift from a rigid target value to a target corridor. This is between 6.5 and 7.5% (48-58 mmol/mol Hb), but should be determined on an individual basis. Therapy goals depend on patient preference, comorbidity, age and life expectancy, quality of life, cultural conditions, psychosocial circumstances and opportunities, and abilities of the affected person.

 

 

Supplementary GLP1 administration

Already in addition to first-line therapy, a GLP1 analogue can be added if the risk of a diabetes-related cardiovascular and/or renal event is high or if clinically relevant cardiovascular disease is already present. GLP1 analogues are preparations that mimic the action of the natural incretin hormone. Incretins are formed in the intestine and regulate blood glucose by stimulating insulin secretion in the pancreas. GLP1 receptor agonists promote insulin secretion from pancreatic beta cells in a glucose-dependent manner, decrease glucagon secretion from alpha cells resulting in decreased glucose release by the liver, increase insulin sensitivity, and slow gastric emptying, thereby reducing the rate at which glucose enters the bloodstream. Another advantage: there is no risk of hypoglycemia.

In addition, GLP1 administration has been shown to lead to weight reduction and, with regard to cardiovascular events, a reduction in morbidity and mortality rates has been observed.

Usually, GLP1 analogues are administered subcutaneously – often once a week is sufficient. In Switzerland, for example, exenatide, liraglutide, lixisenatide and dulaglutide are currently approved. Semaglutide is the first GLP1 analog to be newly available as a tablet for oral administration in addition to subcutaneous administration.

 

Further reading:

  • www.diabetesschweiz.ch/ueber-diabetes.html (last accessed 17.01.2021)
  • www.bfs.admin.ch/bfs/de/home/statistiken/gesundheit/gesundheitszustand/krankheiten/diabetes.html (last accessed on 17.01.2021)
  • www.deutsche-diabetes-gesellschaft.de/behandlung/leitlinien (last accessed on 17.01.2021)

 

CARDIOVASC 2021; 20(1): 30

Autoren
  • Leoni Burggraf
Publikation
  • CARDIOVASC
Related Topics
  • Diabetes
  • GLP-1
Previous Article
  • News from the lung cancer pipeline

First targeted substance in KRAS mutation and bispecific immunotherapy

  • Genetics
  • Market & Medicine
  • Oncology
  • Pneumology
  • RX
  • Studies
View Post
Next Article
  • Benign tumors in childhood

Validated tool for triage in infantile hemangiomas.

  • Congress Reports
  • Dermatology and venereology
  • Pediatrics
  • RX
View Post
You May Also Like
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.